ZLDAF (Zelira Therapeutics) Debt-to-Equity : -1.32 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Zelira Therapeutics Debt-to-Equity?

Zelira Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $2.45 Mil. Zelira Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.50 Mil. Zelira Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-3.00 Mil. Zelira Therapeutics's debt to equity for the quarter that ended in Jun. 2024 was -1.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zelira Therapeutics's Debt-to-Equity or its related term are showing as below:

ZLDAF' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.32 Med: 0.01 Max: 0.02
Current: -1.32

During the past 13 years, the highest Debt-to-Equity Ratio of Zelira Therapeutics was 0.02. The lowest was -1.32. And the median was 0.01.

ZLDAF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs ZLDAF: -1.32

Zelira Therapeutics Debt-to-Equity Historical Data

The historical data trend for Zelira Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics Debt-to-Equity Chart

Zelira Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

-1.32

Zelira Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.02	0.01	-0.74	-1.32

Competitive Comparison of Zelira Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Zelira Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Debt-to-Equity falls into.

Zelira Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zelira Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.448	+	1.503)	/	-2.998
	=	-1.32

Zelira Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.448	+	1.503)	/	-2.998
	=	-1.32

Zelira Therapeutics (OTCPK:ZLDAF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zelira Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zelira Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (OTCPK:ZLDAF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ZLD:Australia

Address

101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website

https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.